What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?

Schrodinger Inc (NASDAQ:SDGR) has recently been touted as one of the best long-term stocks to invest in according to the Bill & Melinda Gates Foundation Trust. With the backing of 31 hedge funds, Schrodinger’s stock has seen a 13% increase over the past month, and analysts are predicting even more upside potential.

In a recent announcement on June 9, Schrodinger revealed that it had finalized an agreement with Mannix Aklian, its former Chief Commercial Officer and Global Head of Software Sales and Marketing. This agreement marks a transition, separation, and release of claims between the two parties.

The company is currently in the process of transitioning its platform to a hosted software licensing model, and management has reported positive progress in this endeavor. In its Q1 2026 results, Schrodinger saw a 12% year-over-year increase in annual contract value (ACV) to $28.4 million. This growth was driven by new deployments and usage scale-ups.

While software revenue was down 21% due to the accelerated transition to hosted software licensing, drug discovery revenue more than doubled to $22.9 million. This increase was attributed to continued progress in Schrodinger’s collaboration portfolio.

Looking ahead, Schrodinger anticipates Q2 2026 ACV to be in the range of $19 million to $23 million. For the full year 2026, the company expects ACV to fall between $218 million and $228 million, indicating a growth of 10% to 15%. Additionally, Schrodinger foresees drug discovery revenue ranging from $55 million to $65 million in 2026, citing Lilly’s planned acquisition of Ajax Therapeutics as validation of the strength of its platform.

Schrodinger Inc specializes in providing software tools for drug discovery and material science. These tools are utilized by pharmaceutical, biotech, chemicals, and energy companies to simulate and model the behavior of molecules, ultimately expediting the design and development of new drugs and materials.

While Schrodinger shows promise as an investment, some believe that other AI stocks may offer greater upside potential with less downside risk. For those seeking an undervalued AI stock poised to benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.

In conclusion, Schrodinger Inc continues to make strides in the field of drug discovery and material science with its innovative software tools. With a strong financial outlook for 2026 and ongoing collaborations, the company remains a compelling option for investors looking to capitalize on the future of technology and innovation.